- Global Pharma News & Resources

aap: Dr. med. Nathalie Krebs elected as new Supervisory Board Chairwoman

DGAP-News: aap Implantate AG / Key word(s): Personnel

04.07.2019 / 14:52
The issuer is solely responsible for the content of this announcement.

aap Implantate AG ("aap") announces that the members of the company's Supervisory Board have elected Ms. Dr. med. Nathalie Krebs (47) as their new Chairwoman. Before, Ms. Dr. med. Krebs was elected to the Supervisory Board of the company by aap's Annual General Meeting held on 21 June 2019 in Berlin with an overwhelming majority (99.99%). Her election is effective from the end of the Annual General Meeting on 21 June 2019 until the end of the Annual General Meeting that resolves on the discharge of the Supervisory Board for the financial year 2021.

"In Ms. Dr. med. Krebs we are delighted to have gained a proven expert in medicine and business as well as a strong personality for aap's Supervisory Board", says Biense Visser, member and previous Chairman of the Supervisory Board at aap. "She looks back on many years of experience in the fields of pharmaceuticals, medical technology and consulting and is additionally active in other Supervisory Bodies of business enterprises with a medical alignment. We are very much looking forward to the cooperation and are firmly convinced that aap will benefit from her comprehensive expertise."

Ms. Dr. med. Krebs is a graduated doctor and studied and graduated at University Basel, Switzerland. She is currently a member of the Board of Directors at several companies and has extensive experience based on different responsible positions in the pharmaceutical industry, in medical technology and with consulting companies, such as Bayer and Boston Consulting Group.


Implantate AG (ISIN DE0005066609) - Prime Standard/Regulated Market - All German stock markets -

About aap Implantate AG
aap Implantate AG is a globally operating medical device company headquartered in Berlin, Germany. The company develops, manufactures and markets trauma products for orthopaedics. The IP protected portfolio includes besides the innovative anatomical plating system LOQTEQ(R) and trauma complementary biomaterials a wide range of cannulated screws as well as standard plates and screws. Furthermore, aap Implantate AG has an innovation pipeline with promising development projects as the antibacterial silver coating technology and magnesium based implants. These technologies address critical problems in surgery that haven't yet been resolved adequately. In German-speaking Europe aap Implantate AG directly sells its products to hospitals, buying syndicates and hospital groups while it uses a broad network of distributors in more than 25 countries at the international level. aap Implantate AG's stock is listed in the Prime Standard segment of Frankfurt Stock Exchange (XETRA: AAQ.DE). For more information, please visit, or download the Company's investor relations app from the Apple's App Store or Google Play.

Forward-looking statement
This release may contain forward-looking statements based on current experience, estimates and projections of the management board and currently available information. They are not guarantees of future performance. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. Many factors could cause the actual results, performance or achievements of aap to be materially different from those that may be expressed or implied by such statements. These factors include those discussed in aap's public reports. Forward-looking statements therefore speak only as of the date they are made. aap does not assume any obligation to update the forward-looking statements contained in this release or to conform them to future events or developments.

For inquiries please contact:

aap Implantate AG; Fabian Franke; Investor Relations; Lorenzweg 5; 12099 Berlin, Germany; Tel.: +49/30/750 19 - 134; Fax.: +49/30/750 19 - 290;

04.07.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at

Language: English
Company: aap Implantate AG
Lorenzweg 5
12099 Berlin
Phone: +49 (0) 30 75 01 90
Fax: +49 (0) 30 75 01 91 11
ISIN: DE0005066609
WKN: 506660
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 836365

End of News DGAP News Service

Editor Details

Last Updated: 04-Jul-2019